Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Arun K Singavi

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
British Journal of Haematology|January 25, 2018
Graft-versus-host disease-associated hepatic portal venous gasArun K Singavi, Nirav N Shah
Journal of Oncology Practice|June 21, 2019
Etanercept for Treatment of Taxane-Induced PneumonitisArun K Singavi, Vijaya Ramalingam, Ben George
The New England Journal of Medicine|August 16, 2018
Daratumumab in Primary Effusion LymphomaNirav N Shah, Arun K Singavi, Alexandra Harrington
Clinical Advances in Hematology & Oncology : H&O|October 18, 2017
Current challenges in the management of essential thrombocythemiaAriel Kleman, Arun K Singavi, Laura C Michaelis
Cancer Treatment and Research|February 7, 2015
Post-transplant lymphoproliferative disordersArun K Singavi, Alexandra M Harrington, Timothy S Fenske
Iscience|November 16, 2018
Immunogenomic Landscape Contributes to Hyperprogressive Disease after Anti-PD-1 Immunotherapy for CancerDonghai Xiong, Yian Wang, Arun K Singavi, et al.
Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis|January 18, 2016
Red cell storage age policy for patients with sickle cell disease: A survey of transfusion service directors in the United StatesMatthew S Karafin, Arun K Singavi, Mehraboon S Irani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 21, 2019
Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical PracticeLindsey E Roeker, Christopher P Fox, Toby A Eyre, et al.
Blood Advances|May 19, 2019
A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLLAnthony R Mato, Lindsey E Roeker, Toby A Eyre, et al.
Haematologica|June 9, 2018
Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United StatesAnthony R Mato, Meghan Thompson, John N Allan, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
British Journal of Haematology|January 25, 2018
Graft-versus-host disease-associated hepatic portal venous gasArun K Singavi, Nirav N Shah
Journal of Oncology Practice|June 21, 2019
Etanercept for Treatment of Taxane-Induced PneumonitisArun K Singavi, Vijaya Ramalingam, Ben George
The New England Journal of Medicine|August 16, 2018
Daratumumab in Primary Effusion LymphomaNirav N Shah, Arun K Singavi, Alexandra Harrington
Clinical Advances in Hematology & Oncology : H&O|October 18, 2017
Current challenges in the management of essential thrombocythemiaAriel Kleman, Arun K Singavi, Laura C Michaelis
Cancer Treatment and Research|February 7, 2015
Post-transplant lymphoproliferative disordersArun K Singavi, Alexandra M Harrington, Timothy S Fenske
Iscience|November 16, 2018
Immunogenomic Landscape Contributes to Hyperprogressive Disease after Anti-PD-1 Immunotherapy for CancerDonghai Xiong, Yian Wang, Arun K Singavi, et al.
Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis|January 18, 2016
Red cell storage age policy for patients with sickle cell disease: A survey of transfusion service directors in the United StatesMatthew S Karafin, Arun K Singavi, Mehraboon S Irani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 21, 2019
Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical PracticeLindsey E Roeker, Christopher P Fox, Toby A Eyre, et al.
Blood Advances|May 19, 2019
A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLLAnthony R Mato, Lindsey E Roeker, Toby A Eyre, et al.
Haematologica|June 9, 2018
Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United StatesAnthony R Mato, Meghan Thompson, John N Allan, et al.
Pageof 1